Literature DB >> 23775853

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

F E Stuurman1, M P Lolkema, A D R Huitema, P M M B Soetekouw, H Rosing, L Rolfe, P Kaur, J H Beijnen, H van Tinteren, E E Voest, J H M Schellens.   

Abstract

Entities:  

Keywords:  CO-101; CP-4126; QT/QTc intervals; bioequivalence; cancer; dFdC; dFdU; formulation; gemcitabine; infusion; lipid; phase 1; phospholipids

Mesh：

Substances：

Year:  2013        PMID： 23775853     DOI： 10.1002/jcph.108

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  3 in total

Review 1.  Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.

Authors:  Pavan P Adiseshaiah; Rachael M Crist; Sara S Hook; Scott E McNeil
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

Review 2.  Pancreatic Cancer Chemoresistance to Gemcitabine.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

3.  Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models.

Authors:  Caixia Wang; Yuanqiang Zheng; Michael A Sand Oval; Solange A Valdes; Zhe Chen; Dharmika S Lansakara-P; Maolin Du; Yanchun Shi; Zhengrong Cui
Journal:  Oncotarget       Date:  2017-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.